Sep 13, 2016 7:00am EDT Can-Fite Receives Notice of Allowance for Psoriasis Patent in Europe Ahead of Phase III Trial
Sep 07, 2016 7:00am EDT Can-Fite to Present at Rodman & Renshaw Conference in New York City on September 12, 2016
Aug 08, 2016 7:00am EDT Can-Fite's Phase II/III Psoriasis Study Results Published in Journal of Drugs in Dermatology
Jul 25, 2016 7:00am EDT Can-Fite Completes Phase II Study Design for CF102 in the Treatment of NASH/NAFLD
Jun 15, 2016 7:00am EDT Can-Fite Reports New Data Showing its Psoriasis Drug May Offer Efficacy Similar to Industry Leading Biologics Without Harmful Side Effects
Jun 07, 2016 7:00am EDT Can-Fite Submits Psoriasis Phase III Protocol and Registration Plan to EMA for Piclidenoson (CF101)
Jun 03, 2016 1:50pm EDT Can-Fite to Exhibit at Bio International Convention in San Francisco on June 6-9, 2016
Jun 01, 2016 7:00am EDT Can-Fite Reaches Agreement with EMA on Pivotal Phase III Clinical Trial with Piclidenoson (CF101) in Rheumatoid Arthritis
